Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
about
Systemic treatments for metastatic cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaSystematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanomaSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyAntitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in MiceMeta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant MelanomaImmunotherapy for Bone and Soft Tissue SarcomasPhase II assessment of talabostat and cisplatin in second-line stage IV melanoma.Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Inhibitory effects of Lang-du extract on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action.Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma[Malignant melanoma: a rare tumor of the nasal cavity--about a series of 10 cases].Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial cProteomic investigation of the sinulariolide-treated melanoma cells A375: effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascadeInduction of apoptosis by 11-dehydrosinulariolide via mitochondrial dysregulation and ER stress pathways in human melanoma cellsChoroidal and cutaneous metastasis from gastric adenocarcinomaHead and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines.Update on use of aldesleukin for treatment of high-risk metastatic melanoma.Role of IL-2 in cancer immunotherapyBiochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline.Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma.Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.The Effect of Bornyl cis-4-Hydroxycinnamate on Melanoma Cell Apoptosis Is Associated with Mitochondrial Dysfunction and Endoplasmic Reticulum Stress.Lentigos, Melanocytic Naevi and MelanomaMelanoma immunotherapy
P2860
Q24194804-A0CE379D-E2B4-4115-BF96-064C63FD235CQ24201908-13BE9C7B-FADF-4AA6-BB3B-997DE36F39CDQ26996629-ECCC3964-7824-4EE8-9F36-F9EF166ED1ACQ27276774-80E1474D-F02B-40D7-9B26-4E5758882841Q27318732-1789F89A-27E6-48DC-8745-BA0B18CE90E8Q28074939-3123F0E1-C121-4859-9BDB-20134CD67965Q28088363-5238ED0E-BACD-4613-A7DE-D577018842A6Q33488712-7998CBC2-48E9-485D-A88C-C30CFA922119Q33829284-863FF131-2E0B-497E-BF42-1BA62116558DQ34000700-58FC527F-3406-45EC-BAED-C3ACDD607DB4Q34297956-3FA2D819-6BC1-4BF6-AF31-A38F1264C52CQ34347631-36E0E0DD-F757-47C1-B077-8F7819C088B3Q34497045-DA9BF3DF-F8AF-4070-94F5-3C0449AE111DQ34511353-94A71562-FC7D-4E9A-B0A8-1439165D9B0CQ34600089-158CEC64-88CF-4BFE-B069-C28DF61E0E72Q34861389-EE78F9FF-1363-4F5D-8DF2-EFEDF23C0E73Q36248410-9E226D78-6830-4C6B-82CE-2D55EDDACB68Q36699323-A8430606-FF5E-4960-8B65-4367BBE649DEQ36919493-787A78E7-C741-4958-84F3-1BDD1BC18BF9Q37031696-61EF457F-CFAF-4471-885F-07D61C3BBE41Q37079072-6FE0F57D-B0BB-4B93-A581-F0C47F49069DQ37153593-8A18DCBD-8EC8-4BEC-96CD-F7C597D9BD97Q38327993-F862AC45-A27A-4EAC-ABF3-18F91ADB9B35Q40188863-B2895437-096E-4D8B-9179-E665304FAA7BQ40477143-A62CF72B-59DC-495E-BDD3-BEFA7B9D2ED5Q41696382-06CDE5F3-2F0F-4758-8298-C96D08C384B4Q54111816-C96BB99A-24CC-400A-8B25-0633E99585A5Q56828381-BFB61A9D-C9B3-4510-A815-5D3135E10F24Q56896842-E6450575-693D-4C41-A9AA-9AB1261813A6
P2860
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@ast
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@en
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@en-gb
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@nl
type
label
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@ast
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@en
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@en-gb
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@nl
prefLabel
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@ast
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@en
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@en-gb
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@nl
P2093
P2860
P3181
P1476
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
@en
P2093
L G O Clark
O A C Clark
P2860
P304
P3181
P356
10.1002/14651858.CD005413.PUB2
P50
P577
2007-01-24T00:00:00Z